-transparent.png){kind=logo}
BACKGROUND Various antineoplastic agents can cause Raynaud's phenomenon, as can malignant diseases themselves. OBJECTIVE To review the clinical characteristics of chemotherapy-induced Raynaud's phenomenon and compare them with those of malignancy-associated Raynaud's phenomenon. CONCLUSIONS Chemotherapy-induced Raynaud's phenomenon most commonly occurs in patients with testicular cancer who receive bleomycin either as a single agent or as part of a multiple-drug chemotherapeutic regimen. It tends to resolve spontaneously, especially after discontinuation of the inducing antineoplastic agent, and rarely causes significant functional impairment. However, it tends to recur with subsequent administration of the drug. In contrast, malignancy-associated Raynaud's phenomenon is rarer, causes more severe symptoms, and usually occurs in older patients with more advanced cancer. CONCLUSIONS As more patients with cancer undergo chemotherapy, physicians should be aware of the potential delayed toxic effects of antineoplastic drugs.
E Toumbis-Ioannou, and
P R Cohen
February 1982,
Annals of internal medicine,
E Toumbis-Ioannou, and
P R Cohen
February 1983,
Annals of internal medicine,
E Toumbis-Ioannou, and
P R Cohen
November 1981,
Annals of internal medicine,
E Toumbis-Ioannou, and
P R Cohen
April 1978,
Cancer treatment reports,
E Toumbis-Ioannou, and
P R Cohen
November 1978,
The Journal of the Medical Society of New Jersey,
E Toumbis-Ioannou, and
P R Cohen
October 1981,
Archives of dermatology,
E Toumbis-Ioannou, and
P R Cohen
December 2007,
Acta ophthalmologica Scandinavica,
E Toumbis-Ioannou, and
P R Cohen
June 1997,
Biological psychiatry,
E Toumbis-Ioannou, and
P R Cohen
April 2007,
Rheumatology international,
